Stanford University
Showing 2,501-2,550 of 34,507 Results
-
Daniel Bernstein
Alfred Woodley Salter and Mabel G. Salter Endowed Professor of Pediatrics
Current Research and Scholarly Interests1. Using iPSC-derived cardiomyocytes to understand hypertrophic cardiomyopathy and heart failure associated with congenital heart disease.
2. Role of alterations in mitochondrial dycamics and function in normal physiology and disease.
3. Differences between R and L ventricular responses to stress,
4. Immune biomarkers of risk after pediatric VAD implantation.
5. Biomarkers for post-transplant lymphoproliferative disorder. -
Jon Bernstein
Professor of Pediatrics (Genetics) and, by courtesy, of Genetics
Current Research and Scholarly InterestsMy research is focused on the diagnosis, discovery and delineation of rare genetic conditions with a focus on neurodevelopmental disorders. This work includes the application of novel computational methods and multi-omics profiling (whole genome sequencing, long-read DNA sequencing, RNA sequencing, methylomics, metabolomics). I additionally participate in an interdisciplinary project to develop induced pluripotent stem cell and assembloid models of genetic neurodevelopmental disorders.
-
Michael Bernstein
Professor of Computer Science and Senior Fellow at the Stanford Institute for Human-Centered AI
BioMichael Bernstein is a Professor of Computer Science at Stanford University, where he is a Bass University Fellow and Senior Fellow at the Stanford Institute for Human-Centered Artificial Intelligence. A nationally bestselling author, Michael focuses on designing social, societal, and interactive technologies. This research has been reported in venues such as The New York Times, TED AI, and MIT Technology Review, and Michael himself has been recognized with an Alfred P. Sloan Fellowship and the Computer History Museum's Tech for Humanity Prize. Michael holds a bachelor's degree in Symbolic Systems from Stanford University, as well as a master's degree and a Ph.D. in Computer Science from MIT.
-
Wendy J. Bernstein
Adjunct Clinical Instructor, Psychiatry and Behavioral Sciences
BioSenior Community Psychiatrist, Wellness Equity Alliance, Medical Director, Project ECHO and Telemedicine for Severe Mental Illness Track to support the Mental Health of SGBV survivors in Democratic Republic of Congo project. Past Associate Medical Director at Casa del Sol, specialty mental health clinic of La Clinica de la Raza in Oakland California from 2013 to July 2021. Previously at Kaiser Permanente, Northern California, from 2000 to 2013, and Contra Costa County Older Adults Clinics from 1995-2000. Graduate of McGill University Faculty of Medicine, Montreal, Canada, and Boston University Psychiatry Residency. Interests include global health, community mental health, Latinx and underserved populations, women's health, and elder care.
-
Greg Beroza
Wayne Loel Professor of Earth Science
Current Research and Scholarly InterestsEarthquake seismology
-
William Berquist, MD
Professor of Pediatrics (Gastroenterology), Emeritus
Current Research and Scholarly InterestsPediatric Gastroenterology, hepatology and nutrition.
-
Gerald Berry
Richard Kempson, M.D., Professor of Surgical Pathology
Current Research and Scholarly InterestsCardiopulmonary and pulmonary transplant medicine; diagnostic surgical pathology
-
Mark Francis Berry, MD
Mylavarapu Rogers Professor of Cardiothoracic Surgery
BioDr. Berry joined the Division of Thoracic Surgery at Stanford in August 2014. He came to Stanford from Duke University, where he had most recently served as Associate Professor. He received his medical degree at the University of Pennsylvania School of Medicine after receiving bachelors and masters degrees in Electrical Engineering at the University of Pennsylvania. He completed his residency in Cardiothoracic Surgery at Duke University Medical Center after performing a residency in General Surgery at the Hospital of the University of Pennsylvania. His Cardiothoracic Surgical training included a year dedicated to Minimally Invasive General Thoracic Surgery, a period that also included an American Association for Thoracic Surgery sponsored Traveling Fellowship at the University of Pittsburgh.
Dr. Berry practices all aspects of thoracic surgery, including procedures for benign and malignant conditions of the lung, esophagus, and mediastinum. He has a particular interest in minimally invasive techniques, and has extensive experience in treating thoracic surgical conditions using video-assisted thoracoscopic surgical (VATS), laparoscopic, robotic, endoscopic, and bronchoscopic approaches. He serves as the co-Director of the Stanford Minimally Invasive Thoracic Surgery Center (SMITS), and has both directed and taught in several minimally invasive thoracic surgery courses.
Dr. Berry also has a Masters of Health Sciences in Clinical Research from Duke University. His clinical research activities mirror his clinical interests and activities in optimizing short-term and long-term outcomes of patients with thoracic surgical conditions. He has more than 150 peer-reviewed publications, most of which are related to both the use of minimally invasive thoracic surgical techniques as well as evaluating outcomes after treatment of thoracic malignancies. His clinical practice and his research both focus on choosing the most appropriate treatment and approach for patients based on the individual characteristics of the patient and their disease process. -
Edward Bertaccini
Professor of Anesthesiology, Perioperative and Pain Medicine (MSD), Emeritus
Current Research and Scholarly Interestsmolecular modeling of anesthetic-protein interactions, molecular modeling of the ligand-gated ion channels
-
Alice Bertaina MD, PhD
Lorry I. Lokey Professor
Current Research and Scholarly InterestsDr. Bertaina is a highly experienced clinician and will play a key role in supporting Section Chief Dr. Rajni Agarwal and Clinical Staff in the Stem Cell Transplant Unit at Lucile Packard Children’s Hospital. She will also continue her research on immune recovery and miRNA, understanding the mechanisms underlying immune reconstitution, Graft-versus-Host Disease (GvHD), and leukemia relapse after allogeneic HSCT in pediatric patients affected by hematological malignant and non-malignant disorders.
-
Lina Margareta Bertling Tjernberg
Visiting Professor, Energy Science & Engineering
BioLina Bertling Tjernberg is Professor in Power Grid Technology at KTH Royal Institute of Technology, Sweden, and Visiting Professor in the Department of Energy Science and Engineering at Stanford University during 2026–2027. Her research focuses on the reliability and resilience of future electric power systems, with particular emphasis on predictive maintenance, reliability-centered asset management, and risk-informed decision support. At Stanford, her research explores resilient power grids, robust optimization, and approaches combining power-system engineering with data-driven and AI-enabled methods.
-
Carolyn Bertozzi
Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor, by courtesy, of Chemical and Systems Biology
BioCarolyn Bertozzi is the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor, by courtesy, of Chemical and Systems Biology and of Radiology at Stanford University, and an Investigator of the Howard Hughes Medical Institute. She completed her undergraduate degree in Chemistry from Harvard University in 1988 and her Ph.D. in Chemistry from UC Berkeley in 1993. After completing postdoctoral work at UCSF in the field of cellular immunology, she joined the UC Berkeley faculty in 1996. In June 2015, she joined the faculty at Stanford University and became the co-director and Institute Scholar at Sarafan ChEM-H.
Prof. Bertozzi's research focuses on fundamental studies of disease-associated glycobiology and the development of new therapeutic modalities that target these pathways. Her inventions include bioorthogonal chemistries for in vivo imaging and bioconjugation, work for which she received the 2022 Nobel Prize in Chemistry. As well, her lab has developed next generation antibody-drug conjugates, lysosome-targeting chimeras (LYTACs), antibody-enzyme conjugates and antibody-lectin chimeras. Several of these new therapeutic modalities have been translated into clinical candidates for treatment of cancer and autoimmune diseases.
In addition to the Nobel Prize, Prof. Bertozzi has been recognized with many honors and awards for both her research and teaching accomplishments. For example, she is an elected member of the National Academy of Sciences, the National Academy of Medicine, the National Inventors Academy and the National Academy of Engineering, the American Academy of Arts and Sciences, the German Academy of Sciences Leopoldina, and she is a Foreign Fellow of the Royal Society. In addition, Prof. Bertozzi received the Priestley Medal of the American Chemical Society, the Welch Award, the Wolf Prize in Chemistry, the Heineken Prize, Lemelson-MIT award for inventors, and a MacArthur "Genius Award". -
Allison Betof, MD, PhD, FASCO
Associate Professor of Medicine (Oncology)
BioDr. Allison Betof is an Associate Professor of Medicine (Oncology), Director of the Melanoma Program, Director of Solid Tumor Cellular Therapy, and Mark & Mary Stevens Endowed Scholar in Melanoma at Stanford University School of Medicine. Dr. Betof completed her MD and PhD at Duke University, Internal Medicine residency at Massachusetts General Hospital (Harvard University) and Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center. Dr. Betof’s laboratory focuses on understanding resistance to immune checkpoint blockade and cellular therapies for melanoma and other solid tumors. She is the Principal Investigator of clinical trials exploring novel treatments for immunotherapy-refractory melanoma and is internationally recognized for her expertise in brain/CNS metastasis and the use of novel cellular therapies. Dr. Betof has been a pioneer in the use of commercial tumor infiltrating lymphocyte (TIL) therapy for the treatment of melanoma and other solid tumors. She has received funding and awards for her clinical and translational investigative work from multiple high-profile organizations, including the American Society of Clinical Oncology (ASCO), National Institutes of Health (NIH), Melanoma Research Alliance, and Melanoma Research Foundation.
